Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) →References: Page already in Cat:Monoclonal antibody stubs using AWB |
Anypodetos (talk | contribs) Added mab_type, updated source; moved structure to drugbox |
||
| Line 3: | Line 3: | ||
| type = mab |
| type = mab |
||
| drug_name = Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan |
| drug_name = Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan |
||
| |
| image = Y-90 tacatuzumab tetraxetan structure.svg |
||
| mab_type = mab |
|||
| source = zu/o |
|||
| target = [[α-fetoprotein]] |
| target = [[α-fetoprotein]] |
||
| CAS_number = 500784-58-7 |
| CAS_number = 500784-58-7 |
||
| Line 28: | Line 30: | ||
}} |
}} |
||
'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' (trade name '''AFP-Cide''') is a [[humanize]]d [[monoclonal antibody]] intended for the treatment of cancer.<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc Statement On A Nonproprietary Name Adopted By The USAN Counil]</ref> The antibody itself, tacatuzumab, is conjugated with a [[chelator]] |
'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' (trade name '''AFP-Cide''') is a [[humanize]]d [[monoclonal antibody]] intended for the treatment of cancer.<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc Statement On A Nonproprietary Name Adopted By The USAN Counil]</ref> The antibody itself, tacatuzumab, is conjugated with a [[chelator]] for [[yttrium-90]]<ref>[http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref>, a [[radioisotope]] which destroys the tumour cells. |
||
The chelator ("tetraxetan") is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The antibody is attached to one of the four carboxyl groups as an [[amide]], and the other three are [[carboxylate anion]]s neutralizing the three positive charges of the yttrium ion. |
|||
<br clear="all" /> |
|||
==References== |
==References== |
||
Revision as of 15:35, 5 April 2010
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | α-fetoprotein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6470H9971N1712O2007S4290Y |
| Molar mass | 145 kDa |
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with a chelator for yttrium-90[2], a radioisotope which destroys the tumour cells.
The chelator ("tetraxetan") is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The antibody is attached to one of the four carboxyl groups as an amide, and the other three are carboxylate anions neutralizing the three positive charges of the yttrium ion.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |